Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Small Cell Lung Carcinoma 27Lymphoma, Large B-Cell, Diffuse 10Lung Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Hodgkin Disease 6Burkitt Lymphoma 6Neuroblastoma 5Medulloblastoma 5Neoplasms, Germ Cell and Embryonal 4Leukemia, Myeloid, Acute 4Small Cell Lung Cancer Extensive Stage 3Seminoma 3Retinoblastoma 3Recurrence 3Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Carcinoma, Neuroendocrine 3Brain Neoplasms 3Wilms Tumor 2Urinary Bladder Neoplasms 2Teratoma 2Sarcoma, Ewing 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroendocrine Neoplasms × Etoposide × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡